Uptake Medical touts InterVapor study results indicating improved lung function

Uptake Medical said today that data from a study recently published in the journal Lancet indicated that patients who underwent therapy using the company’s InterVapor system experienced statistically significant benefits in both lung function and quality of life. The InterVapor uses heated water vapor to reduce bronchoscopic lung volume in patients with heterogenous upper lobe emphysema, the company said. The results are from the company’s Step-Up randomized, controlled, multi-center, multi-national study designed to evaluate the safety and performance of its Intervapor system. “Non-surgical bronchoscopic lung volume reduction has gained clinical traction because the interventions are minimally invasive, with reduced mortality and morbidity when compared to traditional lung volume reduction surgery,” lead author Felix Herth of the Thoraxklinik said in a press release. “The Step-Up study, which involved a staged treatment strategy targeting only the more diseased segments of an upper lobe, has shown that bronchoscopic lung volume reduction as a treatment approach leads to statistically and clinically significant improvements compared with standard care. It allows for precise targeting of only the more diseased segments of a lobe, and enables clinicians to take a personalized approach to treating a patient’s most diseased segments at the initial stage, assessing their response, and then considering further treatment on an individual basis.”...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Respiratory Uptake Medical Source Type: news